相关实验视频
Updated: Jan 9, 2026

07:30
Robot-Assisted Kidney Transplantation
Published on: July 19, 2021
4.2K
基于类固醇的结果与降低免疫抑制的类固醇在儿童脏移植接受者的结果:NAPRTCS研究
Nicole Hayde1, Eliza Blanchette2, Margret Bock2
1Division of Pediatric Nephrology, Children's Hospital at Montefiore, Bronx, New York, USA.
Pediatric transplantation
|December 9, 2025
概括
当前的类固醇最小化 (SM) 免疫抑制在儿科移植接受者 (pKTR) 中显示出改善的结果. 与基于类固醇 (SB) 的疗法相比,SM与更好的功能,生长和更少的并发症有关.
科学领域:
- 儿科脏病学 儿科脏病学
- 移植免疫学 移植免疫学
- 临床结果研究研究
背景情况:
- 在儿科移植 (pKTR) 中的类固醇最小化 (SM) 协议已经随着现代免疫抑制而演变. 以前的研究可能不反映当前的SM疗效.
- 假设:当代SM免疫抑制为pKTR提供了优势,而不会对移植和患者的结果产生负面影响.
研究的目的:
- 评估当前的类固醇最小化 (SM) 免疫抑制与基于类固醇 (SB) 的疗法对儿科移植接受者的影响 (pKTR).
- 在不同的免疫抑制策略下评估pKTR中的移植功能,存活率,线性生长,肥胖和高血压.
主要方法:
- 从2000-2019年使用北美儿科脏试验和协作研究 (NAPRTCS) 数据对3263个pKTR进行回顾性分析.
- 根据移植后30天的皮质类固醇使用情况,将患者分为SM或基于类固醇 (SB) 的组.
- 主要结局:全移植功能 (eGFR) 和生存率. 二次结果:线性生长,肥胖,高血压.
主要成果:
- 与基于类固醇 (SB) 相比,在移植后的1,2,3年内与显著更高的eGFR相关的类固醇最小化 (SM).
- 与显著较小的全移植损失 (p=0.01) 相关的MS,在全移植存活率上没有差异.
- 与SB相比,SM组的线性生长改善,肥胖和高血压率降低.
结论:
- 在儿科移植接受者 (pKTR) 中,当代类固醇最小化 (SM) 免疫抑制与排斥增加,移植功能受损或生存率降低无关.
- 马氏硬化疗法与较低的二次并发症风险有关,例如生长不良,肥胖和高血压.
- 降低类固醇剂量可能是接受基于塔克罗利斯的现代维护疗法的pKTR首选免疫抑制策略.
相关概念视频
Kidney Transplant II: Surgical Procedure
279
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
279
Kidney Transplant I: Introduction
307
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
307
Kidney Transplant III: Nursing Management
289
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
289
Pharmacokinetics in Pediatric Patients: Drug Excretion
194
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
194
Tissue Transplantation
864
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
864
Pharmacokinetics in Pediatric Patients: Drug Metabolism
174
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
174

